Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Favors 'Bio-betters' Over Biosimilars

This article was originally published in PharmAsia News

Executive Summary

Takao Hayakawa of Japan's Pharmaceuticals and Medical Devices Agency recently laid out the philosophy Japan has taken toward biosimilars in its March 2009 guidelines

You may also be interested in...



One Year After Japan Paves Way, Follow-on Biologics Start Blossoming

Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March

One Year After Japan Paves Way, Follow-on Biologics Start Blossoming

Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan

Related Content

UsernamePublicRestriction

Register

SC074461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel